The United States, western Europe, and Japan lead the rest of the world when it comes to funding science (Table 1; Figure  1 ). In these countries, science research at universities and other academic institutions is funded primarily by government agencies that decide which projects to support through a competitive peer review of grant applications. This year, the National Institutes of Health (NIH), the main funding agency for biomedical research in the US, released plans for a major overhaul of its system for reviewing grant proposals-a system first put in place in 1944.
The "renovation" plans include shortening grant applications, providing more incentives and guidance for reviewers, awarding more grants to early career investigators, varying the weight given to different criteria in a proposal, and other changes. "The fundamental peer review process is crucial to everything we do. We are making the process better," says Lawrence Tabak, director of the National Institute of Dental and Craniofacial Research at NIH.
So how do the proposed changes compare to what other government agencies in Europe and elsewhere are doing?
Seeking Input
After doubling of the NIH budget from 1998 to 2003, funding has remained essentially flat at over US $28 billion. At the same time, beginning in 2002, the number of grant applications submitted to NIH increased dramatically. The numbers seemed to have reached a plateau at just under 80,000 applications a year in 2006 (Cell 2006, 125, 823-825) , but this ceiling will be breached in fiscal year 2008. As a result, scientists charged with reviewing applications for the NIH have been feeling increasingly overburdened, raising concerns that the quality of the review process would suffer.
To address the problem, NIH director Elias Zerhouni, who recently announced his resignation, charged an advisory committee, co-chaired by Tabak and Keith Yamamoto at the University of California, San Francisco, to provide recommendations on how to improve the current system. The committee cast a wide net across the research community, including staff at the NIH and other agencies, to catch the best ideas. "We conducted an almost unprecedented level of consultation," says Tabak. Suggestions were sought through emails, phone calls, and written documents, as well as at regional meetings across the country and town hall meetings at NIH. The result was a draft report of recommendations issued in February 2008, inviting comment.
Enhancing NIH Grant Peer Review: A Broader Perspective
Over the next couple of years, NIH will be revising its process of reviewing grant applications. The planned changes will make the NIH system more similar in some ways to those of European funding agencies, while retaining many unique features. Although the proposed changes were prompted primarily by a desire to fix cracks in the system brought to light by a tightening of the NIH budget and record high numbers of grant applications, they will have long-lasting impact, according to Yamamoto. "The way science is done has changed a lot since NIH put a system in place over 60 years ago," he says. "Many of these changes will have an impact even when the funding gets better. They all serve to increase the quality of the science that is funded and change the culture [of review panels]."
Help for the Young One element that almost everyone agreed with was that the grant peer review system should ensure that researchers starting out on their independent careers have the best chance of being successful. The average age of investigators receiving their first NIH Research Project Grant (R01) award has steadily increased from 37 years in 1980 to 42 years today. This is a worrying trend because academic researchers in the US rely on obtaining R01 grants to establish and maintain their labs, as well as to obtain tenure and other promotions.
The NIH asks researchers who apply for an R01 award to indicate whether it is their first NIH application (this does not mean that they are early career investigators, just that they had never applied to NIH before). First-time users of the system are supposed to get a more "lenient" review. But now the NIH plans also to ask applicants to indicate whether they are in the early stages of their careers-in other words, within 10 years of having received their PhD. Reviewers will rate applications of earlystage investigators separately from the pool of submitted applications. "We will parse out applications from the early stage scientists and compare them just to themselves. But they will be reviewed by the same people, using the same criteria and rigor as the applications from more established scientists," says Tabak.
Separating more junior investigators from established ones will not be a feature unique to the NIH system. Many agencies follow the practice. The European Research Council (ERC) has a funding scheme, called the ERC Starting Independent Researcher Grant (http://erc.europa. eu), specifically for researchers establishing their first independent research team, which is run separately from the one for already established investigators. "We thought this was absolutely essential. We thought it would be unfair for the young to compete with fully established scientists," says Fotis Kafatos, chair of immunogenomics at Imperial College, London, and president of the ERC. "We want to give a big boost to people starting their careers. This is often not a high priority at the national level."
The ERC was established in 2007 through the European Council's 7 th Framework Programme to fund basic research across all disciplines and in all European Union (EU) member and associated countries. The agency is funded to the tune of about €1.1 billion (US $1.6 billion) a year for the first funding period from 2007-2013, 40% of which goes to life and medical science research. Awards in this area are typically for a 5 year period and for an average of a million euros-larger and longer grants than those typically received by young researchers at the national level.
Japanese funding agencies are also putting more effort into giving starting researchers greater opportunities. A 2004 survey by the Japan Council for Science and Technology Funding reported that scientists who are 50 years or older receive the bulk of competitively awarded research grants in Japan. Most such grants come from the Ministry of Education, Culture, Sports, Science and Technology. With a budget of 358 billion yen (US $3.4 billion) in 2006, the Ministry is the source of more than three quarters of the country's competitive research grants.
Shorter Is Better
The NIH R01 grant application is one of the longest documents used by any funding agency or foundation worldwide. The "research plan" section of an R01 application is currently about 25 pages. In comparison, for most organizations in the UK for example, the equivalent section is usually 3 to 5 pages long. Most reviewers find that a "short welldefined proposal provides sufficient material for assessment," says Catherine Quinn, head of grants management at The Wellcome Trust. But she adds that American researchers tend to expect longer project descriptions that provide much more detail. "They say 'How can I judge this if I don't know the pH of the buffer?'" says Quinn. The Wellcome Trust, the largest charity in the UK, spends about 600 million pounds (US $1.1 billion) a year to support biomedical research. Its project grants, the closest match to R01 NIH grants, are typically for 3 years and about 150,000 to 300,000 pounds (US $277,000-554,520).
NIH will start asking its investigators to submit shorter (12-page research plan) R01 applications for January 2010 receipt dates. Shorter proposals will not only decrease the workload for reviewers but also, says Tabak, improve the quality of the review process. "We will end up with better grants. Shorter applications force applicants to focus more on the larger picture and less on fine minute details and methodology," he says. "In the new format each applicant will have to make his or her best case for the impact of the proposal, what is innovative and original about it, the feasibility of the project plan, and so on. We don't want to know every buffer condition and molarity. When you provide all the nitty-gritty details reviewers sometimes focus on those and lose focus on the big issues."
If novelty and innovation are what you are after, a shortened research proposal works well according to the Human Frontier Science Program (HFSP). This agency is funded primarily by Japan with almost 50% of the budget coming from other countries, to support teams of collaborating scientists from different countries conducting interdisciplinary research. The first step in the review process for HFSP research grants is the evaluation of a 2-page letter of intent. After reviewing those letters, members of a standing committee select those applicants (about 80 out of 600-700) who will be asked to submit a full application. For the first round of selection "committee members are asked to comment primarily on innovation and whether this is really an international collaboration," says Geoff Richards, director of research grants. The complete applications, which can be up to 15 pages in length, are sent out to several outside reviewers who comment in detail about the project. According to Richards, finding reviewers for the full proposals has not been difficult because most reviewers have enjoyed the broad range and innovative nature of the projects funded by HFSP. "We often have reviewers say 'Thank you for sending me this proposal to review, it is much more interesting than anything I have seen on a national level.'" ERC has a similar two-stage review process with an initial review of a short 2-page synopsis and much more in-depth review of a longer application.
To Amend or Not to Amend
The most controversial issue that the NIH advisory committee had to consider in providing recommendations was the resubmission of grant applications. Currently, if an R01 grant proposal is not approved for funding, the applicant can amend the proposal based on the reviewers' comments and send it back for consideration. If the revised proposal is once again turned down, the applicant has a second, and last, chance to address further criticisms and resubmit an amended application.
The NIH advisory committee found that reviewers tend to favor amended applications over first-time awards. That, however, means that fewer first-time submissions are approved. Since the doubling of the NIH budget ended in 2003, the percentage of first-time applications funded has shrunk from 60% of the total pool to 30%. "For all the right and noble reasons, reviewers are perhaps giving more weight to the fact that a person is in their last chance of amended application. As a result things became skewed," says Tabak. "The concern is that when the very best science is coming in as a first application, its support might end up being delayed."
The NIH advisory committee recommended that all applications be considered new and to do away with amended applications. It also urged that the weakest proposals be marked "not recommended for resubmission." Although many scientists in the community and scientific societies balked at this suggestion, it is not that unusual. Scientists who submit to the ERC cannot file amended applications. In fact, if their application does not make the cut, applicants have to skip a submission cycle before applying again. The Wellcome Trust also does not allow amendments, except for rare cases where the review committee feels strongly that making some changes to an application will make it competitive for funding.
In the end, the NIH settled on middle ground. "The [US research] community felt that feedback was valuable and will help improve science and that having feedback at least once adds value," says Tabak. As a result, NIH is considering separate "percentiling" of new and resubmitted grant applications and permitting only one amended application rather than two. (Percentiling is the process of ranking applications relative to other applications scored by the same study section in the current meeting plus the two previous meetings as a way to account for different scoring behaviors of different study sections.)
Hunting for Reviewers
Many European funding agencies have standing review panels of scientists elected to serve for a specified term. Sometimes these scientists are paid (€450 a day for researchers on ERC panels), but typically they serve on an honorary basis. These elected panels serve a similar function to the NIH study sections, except that their members often seek advice from a pool of outside reviewers, typically from all over the world, selected on a case-by-case basis to comment on a proposal. The reviewers provide their comments for consideration by the review panels who then write the evaluation and make the decisions on funding.
Before 2004, the Deutsche Forschungsgemeinschaft (DFG), the main funding organization for research at universities and other publicly financed research institutions in Germany, had both elected reviewers, responsible for the review of grant proposals, and elected heads of review panels, responsible for making the final suggestions for funding. But having elected reviewers gave the agency too "narrow a base of expertise," says Paul Königs, head of the department of scientific affairs at DFG. "We get about 15,000 proposals per year and we need many more specialists to review these proposals and not just in Germany." As a result, in 2004 the agency changed its statutes. It established review boards whose members are elected by the scientific community in Germany and are responsible for deciding on funding for DFG grant proposals. But the reviews themselves can now be written by scientists anywhere in the world.
Today DFG solicits statements from about 7,000 reviewers annually, 25% of whom are from abroad. "We have to use reviewers from other countries," says Königs. "Compared to the US, Germany is a small country. The scientific community is tightly knit, so sometimes we have conflicts of interest. To avoid those and make sure we are not looking at grants from an encapsulated position, we look for reviewers everywhere, from Switzerland to China."
A country like Ireland-about the size of West Virginia and with a population of just over 4 million people, about 12,000 of whom are researchers (Table 1 )-has always relied on outside reviewers. Since the establishment of Science Foundation Ireland (SFI) in 2000, the main funding agency for basic research, Ireland has had competitive grants, similar to the R01 NIH grants, for its researchers. "All our referees are from outside Ireland," says Frank Gannon, who became SFI director general in July 2007, after leaving his post as executive director of the European Molecular Biology Organisation. Currently, SFI has a budget of €1.4 billion (US $2.0 billion) for the period 2007-2013, translating to about €200 million (US $288 million) per year.
The NIH advisory committee considered several options for a so-called editorial-style scheme of peer review. "In general the scientific community did not embrace any of them," says Yamamoto. "The feeling is that the traditional system of study sections works well. And there is no question that it is funding outstanding science." However, Yamamoto says it is possible that the NIH will pilot some ideas for changing how study sections function. "One idea is to have a standing study section of 18-20 core members but giving them the option to select outside ad hoc reviewers to comment on specific proposals or components of a proposal. That would be one way to give some relief to the system."
Giving Reviewers Flexibility
Agencies like NIH and the National Science Foundation (NSF) in the US use primarily American-based researchers to sit on study sections, review grant proposals, and make decisions about funding. Typically these decisions are made at meetings where the best grant proposals are discussed at length. This rigorous review system has worked well, but the increasing number of grant applications is threatening to overload reviewers.
From fiscal year 2000 to 2006, NSF's overall funding rate for research proposals decreased from 33% to 26%. Similar to NIH, NSF has also experienced an increase in the number of grant proposals submitted to the agency. Through surveys, NSF has determined that the reviewers' workload has increased and that reviews submitted by overworked reviewers may be diminishing in quality. Although NSF has not yet made any drastic changes to its peer review system, it is actively trying to relieve the burden on its reviewers, says Lisa-Joy Zgorski, public affairs specialist at NSF. "We are trying to increase the pool of reviewers and its diversity and are exploring the use of technology to have more 'virtual' panels and web-based reviews to minimize travel." NIH will also be testing similar methods to make the reviewers' job easier. Starting in 2009, reviewers will be given more flexibility regarding their "tour of duty" (such as shorter terms, or the ability to take breaks from serving on a study section). NIH will also test various methods as alternatives for in-person meetings. In addition, reviewers will receive more guidance on how to structure their reviews and what aspects of a proposal to comment on. Starting with reviews conducted in May 2009, reviewers will be asked to provide feedback through scores and critiques for several criteria in a structured summary statement.
These changes and others to be adopted by NIH over the next few years aim to enhance a system that has been the gold standard for research funding for over half a century. They will make the NIH grant peer review system more similar, in some aspects, to those of European funding agencies, while still retaining other unique features that have worked well for the US research community. Whether these changes will make a noticeable difference in obtaining and retaining the most qualified grant reviewers and ensuring that they provide the most useful comments and suggestions-even during difficult economic times-will soon be determined. Regardless, the revision of the grant peer review system will be one of the last major actions of Elias Zerhouni's 6-year tenurethe NIH director announced on September 24 that he will leave NIH by the end of October. "Most people in the community regard this assessment as a very important thing for Zerhouni to have done," says Yamamoto. "I hope the new director will continue with the effort."
